Basic information
- CAS
58-68-4- Standard SMILES
NC(=O)C1=CN([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](O)[C@@H]3O)[C@@H](O)[C@H]2O)C=CC1- InChIKey
BOPGDPNILDQYTO-NNYOXOHSSA-N- Molecular formula
- C21H29N7O14P2
- Average molar mass
- 665.4 g/mol
- Monoisotopic mass
- 665.12477262
Names & identifiers
- Preferred name
- Nadh
- IUPAC
- [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-5-(3-carbamoyl-4H-pyridin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate
- English name
- dihydrodiphosphopyridine nucleotide
- Molecular formula
- C21H29N7O14P2
- Molecular weight
- 665.44
Names & synonyms
Show more names
Database identifiers
- CAS
58-68-4、606-68-8- PubChem CID
- 439153
- DTXSID
DTXSID30889320- ChEMBL
CHEMBL1234616- ChEBI
CHEBI:16908- UNII
- 4J24DQ0916
- EC Number
- 200-393-0
- Nikkaji
- J213.546I
Properties
Computed structural properties
- XLogP
- -5.7
- Topological polar surface area
- 318 Ų
- Hydrogen bond donors
- 8
- Hydrogen bond acceptors
- 19
- Rotatable bonds
- 11
- Heavy atoms
- 44
- Formal charge
- 0
- Complexity
- 1,230
Experimental & physicochemical properties
Melting Point
140.0-142.0 °C
140.0 - 142.0 °C
Physicochemical properties
- Boiling point
- 1081.8 · 1081.8±75.0 °C(Predicted)
- Density
- 2.18 · 2.18±0.1 g/cm3(Predicted)
- solubility
- Water (Slightly)
- pka
- 1.13 · 1.13±0.50(Predicted)
- form
- Solid
- color
- White to Off-White
- Stability
- Light Sensitive, Temperature Sensitive
- InChIKey
- BOPGDPNILDQYTO-NNYOXOHSSA-N
- FDA UNII
- 4 J24DQ0916 · 4J24DQ0916
- EPA Substance Registry System
- 5 · Adenosine 5'-(trihydrogen diphosphate), P'.fwdarw.5'-ester with 1,4-dihydro-1-.beta.-D-ribofuranosyl-3-pyridinecarboxamide (58-68-4)
- TSCA
- TSCA listed
Safety & regulation
Hazard information
Regulatory Information
Chemical: Adenosine 5â²-(trihydrogen diphosphate), Pâ².fwdarw.5â²-ester with 1,4-dihydro-1-.beta.-D-ribofuranosyl-3-pyridinecarboxamide
Adenosine 5'-(trihydrogen diphosphate), P'â5'-ester with 1,4-dihydro-1-.beta.-D-ribofuranosyl-3-pyridinecarboxamide, disodium salt: Does not have an individual approval but may be used under an appropriate group standard
Regulatory information
Regulatory Information
Chemical: Adenosine 5â²-(trihydrogen diphosphate), Pâ².fwdarw.5â²-ester with 1,4-dihydro-1-.beta.-D-ribofuranosyl-3-pyridinecarboxamide
Adenosine 5'-(trihydrogen diphosphate), P'â5'-ester with 1,4-dihydro-1-.beta.-D-ribofuranosyl-3-pyridinecarboxamide, disodium salt: Does not have an individual approval but may be used under an appropriate group standard
Safety data
- tsca
- TSCA listed
Chemistry & industry
Pharmacology
Pharmacodynamics
A coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage. It is found widely in nature and is involved in numerous enzymatic reactions in which it serves as an electron carrier by being alternately oxidized (NAD+) and reduced (NADH). The action of supplemental NADH is unclear. Oral NADH supplementation has been used to combat simple fatigue as well as such mysterious and energy-sapping disorders as chronic fatigue syndrome and fibromyalgia. Researchers are also studying the value of NADH supplements for improving mental function in people with Alzheimer's disease, and minimizing physical disability and relieving depression in people with Parkinson's disease. Some healthy individuals also take NADH supplements orally to improve concentration and memory capacity, as well as to increase athletic endurance. However, to date there have been no published studies to indicate that using NADH is in any way effective or safe for these purposes.
Mechanism of Action
NADH is synthesized by the body and thus is not an essential nutrient. It does require the essential nutrient nicotinamide for its synthesis, and its role in energy production is certainly an essential one. In addition to its role in the mitochondrial electron transport chain, NADH is produced in the cytosol. The mitochondrial membrane is impermeable to NADH, and this permeability barrier effectively separates the cytoplasmic from the mitochondrial NADH pools. However, cytoplasmic NADH can be used for biologic energy production. This occurs when the malate-aspartate shuttle introduces reducing equivalents from NADH in the cytosol to the electron transport chain of the mitochondria. This shuttle mainly occurs in the liver and heart.
Metabolite Pathways
11-beta-hydroxylase deficiency (CYP11B1);17-alpha-hydroxylase deficiency (CYP17);17-Beta Hydroxysteroid Dehydrogenase III Deficiency;2-aminoadipic 2-oxoadipic aciduria;2-Hydroxyglutric Aciduria (D And L Form);2-ketoglutarate dehydrogenase complex deficiency;2-Methyl-3-Hydroxybutryl CoA Dehydrogenase Deficiency;21-hydroxylase deficiency (CYP21);27-Hydroxylase Deficiency;3-Beta-Hydroxysteroid Dehydrogenase Deficiency;Total 46220 pathways, visit the HMDB page for details
Uses & manufacturing
Applications
Usesb-NADH-d4 is labelled b-NADH (N201480, Disodium salt). b-NADH is one of the biologically active forms of nicotinic acid. Serves as a coenzyme of hydrogenases and dehydrogenases. NAD usually acts as a hydrogen acceptor, forming NADH which then serves as a hydrogen donor in the respiratory chain. Present in living cells primarily in the reduced form (NADPH) and is involved in synthetic reactions.
Upstream & downstream products
Upstream raw materials
Downstream products
Suppliers24 total
Additional notes
DefinitionChEBI: A coenzyme found in all living cells; consists of two nucleotides joined through their 5'-phosphate groups, with one nucleotide containing an adenine base and the other containing nicotinamide.
Related reactions
Compound notes
Loading…